XTL Biopharmaceutica Net Worth
XTL Biopharmaceutica Net Worth Breakdown | XTLB |
XTL Biopharmaceutica Net Worth Analysis
XTL Biopharmaceutica's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including XTL Biopharmaceutica's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of XTL Biopharmaceutica's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform XTL Biopharmaceutica's net worth analysis. One common approach is to calculate XTL Biopharmaceutica's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares XTL Biopharmaceutica's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing XTL Biopharmaceutica's net worth. This approach calculates the present value of XTL Biopharmaceutica's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of XTL Biopharmaceutica's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate XTL Biopharmaceutica's net worth. This involves comparing XTL Biopharmaceutica's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into XTL Biopharmaceutica's net worth relative to its peers.
Enterprise Value |
|
To determine if XTL Biopharmaceutica is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XTL Biopharmaceutica's net worth research are outlined below:
| XTL Biopharmaceutica generated a negative expected return over the last 90 days | |
| XTL Biopharmaceutica has high historical volatility and very poor performance | |
| XTL Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (707 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. | |
| XTL Biopharmaceutica has a frail financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke and TTP |
XTL Biopharmaceutica Quarterly Good Will |
|
XTL Biopharmaceutica uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XTL Biopharmaceuticals Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XTL Biopharmaceutica's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know XTL Biopharmaceutica's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XTL Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XTL Biopharmaceuticals Ltd backward and forwards among themselves. XTL Biopharmaceutica's institutional investor refers to the entity that pools money to purchase XTL Biopharmaceutica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Noked Israel Ltd | 2024-09-30 | 198.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 26.5 K | Rhumbline Advisers | 2024-09-30 | 6.5 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
Follow XTL Biopharmaceutica's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.24 M.Market Cap |
|
Project XTL Biopharmaceutica's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.34) | (0.33) |
When accessing XTL Biopharmaceutica's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures XTL Biopharmaceutica's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XTL Biopharmaceutica's profitability and make more informed investment decisions.
Please note, the presentation of XTL Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
Evaluate XTL Biopharmaceutica's management efficiency
XTL Biopharmaceuticals has return on total asset (ROA) of (0.1378) % which means that it has lost $0.1378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. As of December 26, 2024, Return On Tangible Assets is expected to decline to -0.0009. The current year's Return On Capital Employed is expected to grow to -0.33. At present, XTL Biopharmaceutica's Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 4.6 M, whereas Total Assets are forecasted to decline to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (4.84) | (4.60) | |
| Price Book Value Ratio | 2.30 | 2.41 | |
| Enterprise Value Multiple | (4.84) | (4.60) | |
| Price Fair Value | 2.30 | 2.41 | |
| Enterprise Value | 3.7 M | 3.9 M |
The decision-making processes within XTL Biopharmaceutica are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Return On Equity (0.13) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XTL Biopharmaceutica insiders, such as employees or executives, is commonly permitted as long as it does not rely on XTL Biopharmaceutica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XTL Biopharmaceutica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XTL Biopharmaceutica time-series forecasting models is one of many XTL Biopharmaceutica's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XTL Biopharmaceutica's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
XTL Biopharmaceutica Earnings per Share Projection vs Actual
XTL Biopharmaceutica Corporate Management
| Itay CPA | Chief Officer | Profile | |
| Itay Weinstein | Chief Officer | Profile | |
| Shlomo Shalev | CEO Director | Profile | |
| Ronen Kantor | Company Sec | Profile |
Already Invested in XTL Biopharmaceuticals Ltd?
The danger of trading XTL Biopharmaceuticals Ltd is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XTL Biopharmaceutica is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XTL Biopharmaceutica. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XTL Biopharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.